Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men
Objectives: To determine the occurrence of clinically significant decreases in blood pressure (BP) with sildenafil use in normotensive and hypertensive men by means of ambulatory BP monitoring.
Methods: On 2 nights, 49 men (22 hypertensive, 27 normotensive) had their ambulatory systolic BP (SBP), diastolic BP (DBP), and heart rate monitored during the first 3 hours (waking period) and every 30 minutes after midnight for 3 additional hours (sleeping period). No medication was taken on one night; sildenafil 100 mg was taken on the other.
Results: Sildenafil decreased SBP (-6.0 mm Hg; P = 0.0003), DBP (-4.5 mm Hg; P = 0.001), and mean arterial pressure (-5.3 mm Hg; P = 0.00008). The BP-lowering effects of sildenafil did not differ significantly in the normotensive and hypertensive men. Age significantly affected the BP reductions; decreases in SBP, DBP, and mean arterial pressure were greater in men 49 years old and older than in those younger than 49 years old. According to readings averaged over the entire control and treatment periods, 22.7% of hypertensive men and 3.7% of normotensive men experienced SBP reductions of 20 mm Hg or greater (P = 0.08 for comparison of the two groups); the respective values for DBP were 9.1% and 3.7% (P not significant). These reductions were not associated with any hypotensive symptoms. All participants tolerated sildenafil well.
Conclusions: Sildenafil caused small, clinically insignificant reductions in ambulatory BP in active and resting normotensive and hypertensive men. The results of this study suggest that, when used in accordance with the prescribing information and current treatment guidelines, sildenafil should be safe in younger and older men with or without hypertension.
Similar articles
Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Webb DJ, et al. Am J Cardiol. 1999 Mar 4;83(5A):21C-28C. doi: 10.1016/s0002-9149(99)00044-2. Am J Cardiol. 1999. PMID: 10078539 Clinical Trial.
Zusman RM, Prisant LM, Brown MJ. Zusman RM, et al. J Hypertens. 2000 Dec;18(12):1865-9. doi: 10.1097/00004872-200018120-00022. J Hypertens. 2000. PMID: 11132612 Clinical Trial.
Mahmud A, Hennessy M, Feely J. Mahmud A, et al. J Hum Hypertens. 2001 Oct;15(10):707-13. doi: 10.1038/sj.jhh.1001244. J Hum Hypertens. 2001. PMID: 11607801 Clinical Trial.
Jackson G, Montorsi P, Cheitlin MD. Jackson G, et al. Urology. 2006 Sep;68(3 Suppl):47-60. doi: 10.1016/j.urology.2006.05.047. Urology. 2006. PMID: 17011375 Review.
Kloner RA, Zusman RM. Kloner RA, et al. Am J Cardiol. 1999 Sep 9;84(5B):11N-17N. doi: 10.1016/s0002-9149(99)00114-9. Am J Cardiol. 1999. PMID: 10503571 Review.
Cited by
Murtadha M, Raslan MA, Fahmy SF, Sabri NA. Murtadha M, et al. Pharmaceutics. 2021 Jun 13;13(6):876. doi: 10.3390/pharmaceutics13060876. Pharmaceutics. 2021. PMID: 34199328 Free PMC article.
Kim JN, Oh JJ, Park DS, Hong YK, Yu YD. Kim JN, et al. Sex Med. 2019 Dec;7(4):425-432. doi: 10.1016/j.esxm.2019.07.004. Epub 2019 Aug 20. Sex Med. 2019. PMID: 31444051 Free PMC article.
Stembridge M, Ainslie PN, Boulet LM, Anholm J, Subedi P, Tymko MM, Willie CK, Cooper SM, Shave R. Stembridge M, et al. J Physiol. 2019 Feb;597(4):1059-1072. doi: 10.1113/JP275278. Epub 2018 Jun 6. J Physiol. 2019. PMID: 29808473 Free PMC article. Clinical Trial.
Hsiao HL, Langenickel TH, Petruck J, Kode K, Ayalasomayajula S, Schuehly U, Greeley M, Pal P, Zhou W, Prescott MF, Sunkara G, Rajman I. Hsiao HL, et al. Clin Pharmacol Ther. 2018 Mar;103(3):468-476. doi: 10.1002/cpt.759. Epub 2017 Nov 3. Clin Pharmacol Ther. 2018. PMID: 28599060 Free PMC article. Clinical Trial.
Laursen M, Beck L, Kehler J, Christoffersen CT, Bundgaard C, Mogensen S, Mow TJ, Pinilla E, Knudsen JS, Hedegaard ER, Grunnet M, Simonsen U. Laursen M, et al. Br J Pharmacol. 2017 Aug;174(15):2563-2575. doi: 10.1111/bph.13868. Epub 2017 Jul 5. Br J Pharmacol. 2017. PMID: 28548283 Free PMC article.
